Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	39.73B +97.7%
Revenue (ttm)	17.26B +4.3%
Net Income	1.41B
EPS	1.21
Shares Out	1.16B
PE Ratio	28.19
Forward PE	12.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,247,074
Open	34.20
Previous Close	34.41
Day's Range	33.57 - 34.40
52-Week Range	12.47 - 37.35
Beta	0.72
Analysts	Strong Buy
Price Target	37.25 (+9.21%)
Earnings Date	Jan 28, 2026

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 33,950
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Analyst Summary

According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $37.25, which is an increase of 9.21% from the latest price.

Price Target

$37.25

(9.21% upside)

Analyst Consensus: Strong Buy